Our verdict
Pepti lists peptide therapy costs for an average four-week supply, with physician care and shipping included. Charges renew every 28 days, and some products are priced by dose. Check the specific preparation, price and evidence for its proposed use with the prescribing clinician.
Main trade-offs
- Much of the catalog is research-stage peptides that are not approved anywhere, priced and presented like compounded semaglutide
- Four-peptide blends make it hard to know which ingredient you are responding to
Disclosure: Aminoscope is reader-supported. We may earn a commission from partner links, at no extra cost to you. This never changes our assessment. How we make money.
Compounded medicines are not FDA-approved. A licensed clinician must assess whether treatment is appropriate; availability does not establish safety or benefit.
Good fit
Buyers who already know which specific peptide they want, accept that most of the menu is research-stage, and value a published price and a named medical team.
Consider other options if
Anyone who wants treatments with solid human evidence behind them, anyone looking for TRT or ED tablets, or anyone who would rather avoid molecules that no regulator has approved.
Cost and care at a glance
- Category
- Peptide telehealth
- Published cost
- BPC-157 from $209, TB-500 $209, KPV $229, CJC-1295/ipamorelin $239, sermorelin $229, tesamorelin from $249, MOTS-c from $259; per 4 weeks, all-in; 50 states
- Insurance
- Cash-pay, no insurance
- Visit
- Quiz intake / Async intake
- Availability
- All 50 states
Our review in detail
Full assessment
Pepti is open about the things buyers usually have to dig for. It publishes an all-in price against every product (no membership fee, physician care and shipping included), names the two physicians who lead its medical team, names a partner pharmacy, says each batch is tested by an outside lab, and spells out its compounding and off-label disclosures in full. It serves all 50 states. The issue is what is on the shelf. The catalog has grown to about 60 products, and much of it is research-stage: BPC-157, TB-500, KPV, MOTS-c, epitalon, AOD-9604, SS-31, adipotide, SLU-PP-332, FOXO4-DRI, dihexa and blends that include IGF-1 LR3. None of these is an approved drug anywhere, and most have little or no controlled human evidence. The price list treats them the same as compounded semaglutide. The homepage also shows a bare "FDA / Cleared" badge beside its HIPAA and CLIA badges; the only FDA-cleared item on the site is its injection pen, a device, not any medication.
What it is
A peptide-led telehealth platform run by pepti LLC of Newark, Delaware, with about 60 products across recovery, weight loss, anti-aging, skin and hair, cognition, sleep, immunity, muscle and intimacy. It sells single peptides as vials (a prefilled pen is listed but sold out), a range of branded four-peptide blends (SHRED, TITAN, ETERNAL, FUSION and others), compounded semaglutide and tirzepatide, NAD⁺ and glutathione injections, at-home blood panels, and a supplement pack. Its men's-hormone page describes TRT and enclomiphene but lists no available treatments, and its intimacy line is peptides only (PT-141, oxytocin and kisspeptin); it does not sell ED drugs such as tadalafil, sildenafil or Trimix. For testosterone itself, the MangoRx review covers a cash-pay TRT service whose medication and lab charges need confirming separately.
How care works
Online intake reviewed by a physician licensed in your state, which Pepti says happens within four hours; for some products it also asks for recent bloodwork, which you can upload or buy as an at-home panel. Pepti says every case is reviewed by a licensed physician rather than an algorithm, and names the leads of its medical team: Dr. Gene Lee, MD (medical director, board-certified in family medicine) and Dr. Laeeq Butt, MD, MBA (chief medical officer, board-certified in internal medicine). The physicians are independent, and Pepti is explicit that it is a technology platform, not a pharmacy or a healthcare provider. Prescriptions go to independent 503A compounding pharmacies; Olympia Pharmacy is named as one, and the dispensing pharmacy's name and address are printed on your label. Pepti says the pharmacies are PCAB-accredited and that each batch is tested by an outside lab for sterility, endotoxins, potency, purity and identity before release. Orders ship free in unbranded, tamper-evident packaging, with cold packing where needed.
Costs, billing and cancellation
Every product card shows one all-in price for an average four-week supply, with "no membership fee, this is the full price", physician care and shipping included. The Lttl review shows what a full price ladder looks like, from $149 for four weeks of sermorelin to $1,188 for 52. The medication renews every 28 days until you cancel. Payment is taken at checkout, before the physician reviews your intake, and refunded in full (within 5 to 10 business days) if the physician declines. Some lines are priced by dose. Compounded semaglutide runs from $99 at the 0.25 mg starter dose to $199 at 2.5 mg, and tirzepatide from $159 at 2.5 mg to $319 at 15 mg, so the $99 headline is a first-month figure for most people, not the maintenance price. Other examples: BPC-157 $209 (5 mg) to $299 (30 mg), TB-500 $209, BPC-157 with TB-500 $259 to $319, KPV $229, CJC-1295 with ipamorelin $239, sermorelin $229 or $259, tesamorelin $249 to $349, MOTS-c $259 to $349, epitalon $249 or $279, GHK-Cu $239 or $269, NAD⁺ $249 (1,000 mg) or $279 (2,000 mg), glutathione $199 or $249, AOD-9604 $229, and most four-peptide blends $249 to $289. Intimacy: PT-141 $259 (about an 11-week supply), kisspeptin $229, oxytocin $239. At-home blood panels are $149 each, or $129 a month on a subscription. Cancel anytime from your dashboard; a supply that has shipped is not refunded, and a prepaid three-supply order is non-refundable once placed unless the physician declines. Cash-pay only.
Medication and evidence
Compounded, and disclosed properly. Pepti's compounded-medication page states that compounded medications are not FDA-approved, that the FDA does not review them for safety, effectiveness or quality, that they may not undergo the same testing as approved drugs, and that many of its peptides are prescribed off-label, with an explanation of what that means. The difficulty is the menu itself. Semaglutide and tirzepatide are compounded versions of approved drugs with strong trial evidence behind the branded products. Most of the rest are not approved anywhere: BPC-157, TB-500, KPV, MOTS-c, epitalon, AOD-9604, SS-31 (elamipretide), adipotide, SLU-PP-332, FOXO4-DRI, ARA-290 and dihexa are research-stage molecules with little or no controlled human outcome evidence, and blends add IGF-1 LR3 and melanotan II. In July 2026 the FDA's compounding advisory committee voted, against its own staff scientists' advice, to recommend BPC-157, TB-500, KPV, MOTS-c, epitalon and semax for the list of substances pharmacies may compound; the vote is advisory, and the FDA has not yet acted on it. Combining four such peptides in one vial makes it even harder to know what is doing what. Sermorelin and tesamorelin act on a real growth-hormone axis, injected NAD⁺ has no controlled human outcome trials, and PT-141 is FDA-approved only for low sexual desire in premenopausal women. Individual results vary.
Pros and watch-outs
What we like
- An all-in price published against every product, with no membership fee and no quote-gating
- Names the physicians who lead its medical team; a physician licensed in your state reviews every case
- Names a partner pharmacy, prints the dispensing pharmacy on your label, and says each batch is lab-tested before release
- Thorough compounding and off-label disclosures
- Serves all 50 states, with a refund if the physician declines
- At-home blood panels sold alongside the therapies they should guide
Watch-outs
- Much of the catalog is research-stage peptides that are not approved anywhere, priced and presented like compounded semaglutide
- Four-peptide blends make it hard to know which ingredient you are responding to
- Semaglutide and tirzepatide prices rise with the dose; the $99 and $159 headlines are starter doses
- The homepage shows a bare "FDA / Cleared" badge; nothing it sells as medication is FDA-cleared
- Payment is taken before the physician reviews your intake (refunded if declined)
- No TRT, enclomiphene or ED tablets on sale; the men's-hormone page lists no available treatments
Best for
Buyers who already know which specific peptide they want, accept that most of the menu is research-stage, and value a published price and a named medical team.
Who should look elsewhere
Anyone who wants treatments with solid human evidence behind them, anyone looking for TRT or ED tablets, or anyone who would rather avoid molecules that no regulator has approved.
Research relevant to Pepti
Explore the evidence and its limits. Findings apply to the formulation, route and population studied; they do not establish the quality or effectiveness of a provider’s products.
- BPC-157 dosage and safety: why there is no validated human dose
The honest answer to a heavily-searched query: no established human dose, no dose-ranging trial, no approval, and no long-term safety data. Here is why.
- TB-500 and thymosin beta-4: separating the trials from the hype
Real Phase 2 dry-eye data, deep preclinical neuro/cardiac work, and a recovery-market use that was never actually tested.
- KPV peptide: what the evidence actually shows (benefits, dosage talk, and side effects)
KPV is the anti-inflammatory tripeptide tail of α-MSH, sold for gut, inflammation, wound-healing and skin. The mechanism is real and the mouse data are real — but there are essentially no human trials. A straight read of where the science stands.
- CJC-1295 & ipamorelin dosage: the circulated numbers vs. what's actually proven
There's no FDA-approved dose for either peptide. We explain the pharmacology behind the microgram figures people circulate (the saturation-dose idea, the timing, the stack logic) and why none of it is clinically validated.
- Sermorelin benefits: does it work? What the trials show
A real GHRH drug, read against the anti-aging pitch: an approved growth-hormone-releasing analog with a pediatric track record, and a longevity case built more on biomarkers than outcomes.
- Tesamorelin (Egrifta): what it's actually FDA-approved for, and the evidence
A real, approved GHRH analog — for HIV-associated lipodystrophy specifically. What the pivotal trials showed, and why the longevity use is an extrapolation.
- Epitalon (epithalon): the honest evidence behind the telomerase and longevity claims
Marketed for telomerase activation and life extension. The supporting science is old, small, and almost entirely from one Russian lab — and largely unreplicated.
- MOTS-c peptide: benefits, side effects and what the evidence shows
Real mitochondrial biology, absent human evidence: a genuine mitochondrial-derived peptide with interesting rodent data on metabolism and exercise, but no human outcome trials. Promising biology, not a proven therapeutic.
- SS-31 peptide (elamipretide): benefits, evidence and approval status
An elegant mitochondrial mechanism meets a hard clinical record: a cardiolipin-binding peptide with a failed myopathy trial and a narrow, confirmation-pending Barth syndrome approval. A straight read.
- GHK-Cu: the copper peptide between real skincare and overclaim
A decades-deep molecule with a credible topical story — and systemic anti-aging claims that outrun the human data.
- Glutathione: the master antioxidant, and where the evidence actually is
Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.
- NAD+ precursors (NR and NMN): what the human trials actually show
They raise NAD+ and look safe short-term, but human evidence is surrogate-marker level, and no trial shows they extend healthspan.
- 5-Amino-1MQ: an elegant mechanism with no human trials
An NNMT inhibitor that reverses obesity in mice by sparing the NAD+ pool — without reducing food intake. The mechanism is plausible; the human evidence is nonexistent.
- AOD-9604: the “anti-obesity drug” peptide that failed its own trials
A synthetic growth-hormone tail fragment built to burn fat. Its mechanism is real and its safety was clean — but the pivotal human obesity trial showed no significant weight loss versus placebo, and the program was discontinued.
- What the semaglutide weight-loss trials actually showed
STEP 1, STEP 4 and SELECT, plus oral and higher-dose semaglutide trials: weight loss, withdrawal, cardiovascular benefit and the limits of comparison.
- PT-141 (bremelanotide): the evidence on a peptide that is actually FDA-approved
Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women, with phase-3 trial evidence. A straight read of what's proven — and where off-label use goes beyond it.
- Kisspeptin: real reproductive-axis science, unproven as a sold therapy
A genuine human hormone atop the testosterone axis, with serious early human research — but the marketed libido and T-booster products are off-label extrapolations at unestablished doses.
How Pepti compares
A few alternatives worth a look, depending on what you’re optimizing for.
Our Oak Longevity review and HealthRX review describe what each service publishes about pricing, billing and cancellation.
- Oak Longevity
Low-cost sermorelin within a broader longevity stack
See Oak Longevity → - HealthRX
Compounded sermorelin within a broad longevity and weight-care menu
See HealthRX →
Rehydra+ WellnessBuyers who want dose-by-dose GLP-1 prices and a call with a provider before committing
See Rehydra+ Wellness →
More peptide telehealth reviews: TRT KingdomTrueMeTyde WellnessValhalla VitalityVea HealthVigorMeds
Peptides & longevity
How we assessed this. This review is based on Pepti’s own website and published terms, read for pricing transparency, clinical oversight, medication clarity and access against our editorial methodology. We publish no fabricated ratings or first-hand outcomes. A partnership never changes the assessment — see how we make money.
Frequently asked
- Is Pepti "FDA cleared"?
- No medication it sells is. The homepage shows an "FDA / Cleared" badge beside HIPAA, CLIA and CAP badges without saying what it refers to; the only FDA-cleared item on the site is its prefilled injection pen, which is a device (and currently sold out). Pepti's own compounded-medication page states that compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality. "FDA-registered pharmacy" means the facility is registered, not that a product is cleared.
- Who reviews the intake?
- A physician licensed in your state, usually within four hours by Pepti's account. Its medical team is led by Dr. Gene Lee, MD, the medical director, board-certified in family medicine, and Dr. Laeeq Butt, MD, MBA, the chief medical officer, board-certified in internal medicine. Pepti says decisions are made by a licensed physician, not an algorithm.
- Are the peptides Pepti sells approved drugs?
- Mostly not. Semaglutide and tirzepatide are compounded versions of approved drugs. BPC-157, TB-500, KPV, MOTS-c, epitalon, AOD-9604, SS-31, adipotide, SLU-PP-332, FOXO4-DRI, dihexa and the blends built from them are research-stage molecules that no regulator has approved, and most have little controlled human evidence. The FDA's compounding advisory committee voted in July 2026 to recommend six of them for compounding, but that vote is advisory and the FDA has not yet acted on it. Pepti's price list does not separate the two groups, so you have to.
- How much does semaglutide cost at Pepti?
- It depends on the dose: $99 at the 0.25 mg starter dose, $109 at 0.5 mg, $129 at 1 mg, $179 at 1.7 mg, $189 at 2 mg and $199 at 2.5 mg, each for about a four-week supply with physician care and shipping included. Tirzepatide runs $159 at 2.5 mg to $319 at 15 mg. Budget on your maintenance dose, not the starter price.
- Does Pepti sell TRT or ED tablets?
- Not at the moment. Its men's-hormone page describes testosterone, HCG and enclomiphene but lists no available treatments, and its intimacy line is PT-141, oxytocin and kisspeptin only. It does not sell ED drugs such as tadalafil, sildenafil or Trimix.
- Is Pepti legit?
- Pepti is a peptide telehealth service you reach through an online questionnaire and an online intake a clinician reviews. What it publishes up front: BPC-157 from $209, TB-500 $209, KPV $229, CJC-1295/ipamorelin $239, sermorelin $229, tesamorelin from $249, MOTS-c from $259; per 4 weeks, all-in; 50 states. It is cash-pay and states it does not bill insurance. Before you pay, ask in writing about your selected charge, billing interval, supply and required fees and which medications it dispenses.
